CN1254716A - High-stereoselectivity synthesization of 24R,25- and 24S, 25-dihydroxysteroid - Google Patents

High-stereoselectivity synthesization of 24R,25- and 24S, 25-dihydroxysteroid Download PDF

Info

Publication number
CN1254716A
CN1254716A CN 99124007 CN99124007A CN1254716A CN 1254716 A CN1254716 A CN 1254716A CN 99124007 CN99124007 CN 99124007 CN 99124007 A CN99124007 A CN 99124007A CN 1254716 A CN1254716 A CN 1254716A
Authority
CN
China
Prior art keywords
synthetic method
reaction product
called
short
courage steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 99124007
Other languages
Chinese (zh)
Other versions
CN1098273C (en
Inventor
周向东
周维善
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Organic Chemistry of CAS
Original Assignee
Shanghai Institute of Organic Chemistry of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Organic Chemistry of CAS filed Critical Shanghai Institute of Organic Chemistry of CAS
Priority to CN99124007A priority Critical patent/CN1098273C/en
Publication of CN1254716A publication Critical patent/CN1254716A/en
Application granted granted Critical
Publication of CN1098273C publication Critical patent/CN1098273C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

the present invention relates to a process for synthesizing 24R, 25- or 24S, 25-dihydroxysteroid compounds by improved sharpless asymmetrical dihydroxylation reaction, which features high reaction speed, high stereoselectivity and industrialized production.

Description

The Synthetic 2 4R of patent highly-solid selectively, 25-and 24S, 25-dihydroxyl steroidal compounds
The present invention relates to improved Sharpless asymmetric dihydroxylation reaction, specifically a kind of from Δ 24-steroidal compounds highly-solid selectively Synthetic 2 4R, 25-and 24S, the method for 25-dihydroxyl steroidal compounds.
As everyone knows, the Sharpless asymmetric dihydroxylation reaction has been obtained satisfied result to the asymmetric dihydroxylation of general olefin(e) compound, in the tertiary butanol and water solvent, adds three normal K usually 3Fe (CN) 6, three normal K 2CO 3, monovalent CH 3SO 2NH 2Potassium osmate (K with catalytic amount 2OsO 2(OH) 4) and 1, two (9-O the dihydro-quinidine)-2 ((DHQD) of 4- 2PHAL) or 1, two (9-O dihydro Kui the Buddhist nun)-2 ((DHQ) of 4- 2PHAL), under the room temperature, stir, add olefine reaction to reacting completely.But for steroidal compounds, reaction result is undesirable, its cis-selectivity generally not high (10: 1～96: 4), and long reaction time generally needs 3～6 days.(K.B.Sharpless，Chem.Rev.1994，94，2483～2547；E.J.Corey.Tetrahedron?Lett.1998，39，9351～9354；CA127：34408(1998)：Eur.Pat.Appl.EP?776905)。So people expect to improve stereoselectivity, shorten the Synthetic 2 4R of synthetic method, the especially highly-solid selectively in reaction times, 25-or 24S, the method for 25-dihydroxyl steroidal compounds.
The purpose of this invention is to provide a kind of improved Sharpless asymmetric dihydroxylation reaction, be used for the Synthetic 2 4R of highly-solid selectively, 25-or 24S, 25-dihydroxyl steroidal compounds.
Method of the present invention is in the tertiary butanol and water mixed solvent, Δ 24-steroidal compounds and K 3Fe (CN) 6, K 2CO 3, CH 3SO 2NH 2K with catalytic amount 2OsO 2(OH) 4(DHQD) 2PHAL or (DHQ) 2PHAL reacts to room temperature at 0 ℃, during reaction, adds second kind of solvent, to improve stereoselectivity and to shorten the reaction times.Added second kind of solvent is tetrahydrofuran (THF) (THF), N, dinethylformamide (DMF), glycol dimethyl ether (DME), acetonitrile, t-butyl methyl ether (MBE), ether, isopropyl ether, acetone, butanone, 1,6-dioxane, N, N-dimethyl acetyl ammonia etc.After adding above-mentioned solvent, reacted 10～20 hours, acquisition that can highly-solid selectively has various A, the 24R of B-ring structure, 25-or 24S, 25-dihydroxyl steroidal compounds.
The Δ that is adopted among the present invention 24-steroidal compounds has following molecular formula:
Figure A9912400700041
R wherein 1Or R 2=methoxy methyl ether (being called for short MOMO), THP trtrahydropyranyl (being called for short THP), acetoxyl group (being called for short AcO), OCH 2CH 2O, OH, H, benzoyl (being called for short PhCOO), methanesulfonates (is called for short MeSO 2O), p-toluenesulfonic esters (being called for short TsO), O, tertiary butyl dimethyl-silicon ether (being called for short TBSO), benzyl (being called for short Bn); R 3=α-or β-H, or R 3R 4=two keys, R 4Or R 5=MOMO, THP, AcO, OCH 2CH 2O, OH, H, PhCOO, MeSO 2O or TsO, O; Or R 4R 5=O.R 6Or R 7=MOMO, THP, AcO, OCH 2CH 2O, OH, H, PhCOO, MeSO 2O, TsO, O.R 6R 7＝O。
When adopting method of the present invention, can be with second kind of above-mentioned dissolution with solvents Δ 24-steroidal compounds joins this solution in the solution of above-mentioned tertiary butanol and water and other reagent again and reacts.
In the method for the invention, Δ 24-steroidal compounds, K 3Fe (CN) 6, K 2CO 3, CH 3SO 2NH 2, K 2OsO 2(OH) 4, (DHQD) 2PHAL or (DHQ) 2The mol ratio of PHAL is 1: 1～5: 1: 1～5: 0.5～3: 0.005～0.01: 0.005～0.01.
In the inventive method, in the mixing solutions of the tertiary butanol and water that adopts, the volume ratio of the trimethyl carbinol and water is 1: 0.5～2.Δ in the reaction 24The amount ratio of-steroidal compounds and tertiary butanol and water is every mole of Δ 24-steroidal compounds adds the mixing solutions of 1～10 liter tertiary butanol and water.
Adopt method of the present invention can obtain the 24R of following structure, 25-or 24S, 25-dihydroxyl steroidal compounds.
Figure A9912400700051
R wherein 1Or R 2=methoxy methyl ether (being called for short MOMO), THP trtrahydropyranyl (being called for short THP), acetoxyl group (being called for short AcO), OCH 2CH 2O, OH, H, benzoyl (being called for short PhCOO), methanesulfonates (is called for short MeSO 2O), p-toluenesulfonic esters (being called for short TsO), O, tertiary butyl dimethyl-silicon ether (being called for short TBSO), benzyl (being called for short Bn); R 3=α-or β-H, or R 3R 4=two keys, R 4, R 5, R 6=MOMO, THP, AcO, OCH 2CH 2O, OH, H, PhCOO, MeSO 2O or TsO, O; Or R 4R 5=O, R 6Or R 7=MOMO, THP, AcO, OCH 2CH 2O, OH, H, PhCOO, MeSO 2O, TsO, O.R 6R 7＝O。R 8, R 9=H or OH.In other words, can be the compound of following structure respectively:
Figure A9912400700052
As 5 β-3 α, 6 alpha, alpha-dimethyl oxygen ylmethyl-3 α, 6 α, 24R, 25-tetrahydroxy courage steroid glycol, 5 β-3 α, 6 alpha, alpha-dimethyl oxygen ylmethyl-3 α, 6 α, 24S, 25-tetrahydroxy courage steroid glycol, Δ 5-3 β-ethanoyl-3 β, 24R, 25-trihydroxy--courage steroid glycol, Δ 5-3 β-ethanoyl-3 β, 24S, 25-trihydroxy--courage steroid glycol, Δ 5Silica-based-3 β of-3 β-(tertiary butyl-dimethyl), 24R, 25-trihydroxy--courage steroid glycol, Δ 5Silica-based-3 β of-3 β-(tertiary butyl-dimethyl), 24S, 25-trihydroxy--courage steroid glycol or the like.The 24R of the high-optical-purity of gained, 25-or 24S, the 24R that 25-dihydroxyl steroidal compounds can be respectively applied for synthetic osteoporosis disease as intermediate, 25-dihydroxyl VD 3, the anti-hypercholesterolemia ester of lxr agonist disease 24S, 25-epoxy cholesterol, 24S-hydroxycholesterol and some Δs 25Antineoplastic natural compoundss such as-24R-or 24S-hydroxycholesterol.
Adopt method of the present invention, Synthetic 2 4R that not only can highly-solid selectively, 25-or 24S, 25-dihydroxyl steroidal compounds, its diastereomeric excess value (de%) is up to 95～100%, and the reaction times also foreshortened to 10～20 hours by 3～6 days, be the method that is suitable for suitability for industrialized production.
Help further to understand the present invention by following examples, but can not limit content of the present invention:
Embodiment 15 β-3 α, 6-methoxymethyl-3 α, 6 α, 24R, 25-tetrahydroxy courage steroid glycol 2
In the 25ml egg type bottle, add magneton, 495mg (1.5mmol) K 3Fe (CN) 6, 207mg (1.5mmol) K 2CO 3, 48mg (0.5mmol) MeSO 2NH 2, 24mg (5%mol) (DHQD) 2PHAL, and 8mgK 2OsO 2(OH) 4And 3～5ml trimethyl carbinol, 3～5ml H 2O (1: 1) after stirring, is chilled to 0 ℃, stirs 20 minutes, adds the isopropyl ether contain 245mg (0.5mmol) compound 1 (or ether, t-butyl methyl ether, butanone etc.) solution, stirs 16h in 0 ℃ to room temperature, and raw material disappears.0 ℃, add 0.75gNa 2SO 3Stirred 30 minutes under the room temperature.3 * 15ml ethyl acetate, 3 * 50ml 2NKOH, 3 * 50ml5%HCl, the saturated NaHCO of 3 * 50ml 3, the saturated NaCl washing of 3 * 50ml is neutral, anhydrous Na 2SO 4Dry remove desolvate spumescence solid crude product 274mg, rapid column chromatography gets compound 2 223mg, yield 85%, d.e.99.74%
Compound 2:
[α] D 18+25.64°(C，1.04，CHCl 3)
MS(EI)(m/z)：506(M-H 2O)，400(M-HOCH 2OCH 3)，383(M+1-2HOCH 2CH 3-H 2O)，
IR(film)cm -1：3454(OH)，2944，1466，1378，1211，1037，
1HNMR (300MHz, CDCl 3) δ ppm:0.64 (3H, s, 18-H 3), 0.91 (3H, d, J=4.8Hz, 21-H 3) 0.93 (3H, s, 19-H 3),, 3.36 (3H, s, OCH 3), 3.37 (3H, s, OCH 3), 3.51 (1H, m, 3 β-H), 3.90 (1H, m, 6 β-H), 4.62 and 4.64 (2H, dd, J 1=J 2=6.80Hz, OCH 2O), 4.67 and 4.71 (2H, dd, J 1=J 2=6.80Hz, OCH 2O)
Embodiment 25 β-3,6-dimethoxy-methyl-3 α, 6 α, 24S, 25-tetrahydroxy courage steroid glycol 3
In the 25ml egg type bottle, add magneton, 245mg (0.5mmol) K 3Fe (CN) 6, 207mg (1.5mmol) K 2CO 3, 48mg (0.5mmol) MeSO 2NH 2, 27mg (5%mol) (DHQ) 2PHAL, and 6mgK 2OsO 2(OH) 4And 3～5ml trimethyl carbinol, 3～5mlH 2O (1: 1) after stirring, is chilled to 0 ℃, stirs 20 minutes, adds the glycol dimethyl ether contain 245mg (0.5mmol) compound 1 (or acetonitrile, t-butyl methyl ether, ether, 1,6-dioxane, N, N-dimethyl acetyl ammonia) solution.Stir 16h in 0 ℃ to room temperature, raw material disappears.0 ℃, add 0.75gNa 2SO 3Stirred 30 minutes under the room temperature.3 * 15ml ethyl acetate, 3 * 50ml 2NKOH, 3 * 50ml5%HCl, the saturated NaHCO of 3 * 50ml 3, the saturated NaCl washing of 3 * 50ml is neutral, anhydrous Na 2SO 4Drying, remove desolvate spumescence solid crude product 255mg, rapid column chromatography (pet:acetone/10: 1) compound 3 229mg, yield 87% d.e.97.80%
Compound 3:
[α] D 18-22.89°(C，1.11，CHCl 3)
MS(EI)(m/z)：463(M-HOCH 2OCH 3)，399(M+1-HOCH 2OCH 3-2HOCH 3)，382(M-2HOCH 20CH 3-H 2O)，341((M-2HOCH 2OCH 3-H 2O)
IR(film)cm -1：3462(OH)，2943，2885，1467，1380，1146，1101，1037，
1HNMR(300MHz，CDCl 3)δppm：0.64(3H，s，18-H 3)，0.90(3H，s，19-H 3)，0.93(3H，d，J＝6.58Hz，21-H 3)，3.36(3H，s，OCH 3)，3.37(3H，s，OCH 3)，3.51(1H，m，3β-H)，3.90(1H，m，6β-H)，4.63(2H，s，OCH 2O)，4.67(2H，dd，J 1＝6.75Hz，J 2＝6.70Hz，OCH 2O)
Ultimate analysis (C 31H 56O 61/2 H 2O): calculated value: C, 69.75%; H, 10.76%
Measured value: C, 69.64%; H, 10.92%
Embodiment 3 Δs 5-3-ethanoyl-3 β, 24R, 25-trihydroxy-courage steroid glycol 5
Figure A9912400700071
In the 25ml egg type bottle, add magneton, 1.158g (3.51mmol) K 3Fe (CN) 6, 484mg (3.51mmol) K 2CO 3, 105mg (1.13mmol) MeSO 2NH 2, 46mg (5%mol) (DHQD) 2PHAL, and 4mg (1%mol) K 2OsO 2(OH) 4And 15-20ml t-BuOH-H 2O (1: 1) after stirring, adds the N that contains 500mg (1.17mmol) raw material 4, dinethylformamide (or glycol dimethyl ether, acetonitrile, t-butyl methyl ether, 1,6-dioxane, N, N-dimethyl acetyl ammonia) solution, raw material disappears substantially behind the 20h, is chilled to 0 ℃, adds 1.755gNa 2SO 3Stir 2h.Add the 50ml ethyl acetate, 3 * 60ml 2NKOH, 3 * 60ml0%HCl, the saturated NaHCO of 3 * 60ml 3, the saturated NaCl washing of 3 * 60ml, anhydrous Na 2SO 4Dry remove desolvate crude product 623mg, behind the recrystallization compound 5 441mg, yield 82%, 99.4%de.
Compound 5:
mp：162.4～163.8℃
[α]-25.28°(C，0.352，CHCl 3)
MS(EI)(m/z)：400(M-HOAc)，382(M-HOAc-H 2O)
IR(KBr)cm -1：3475(OH)，2965，2866，1733(CH 3CO 2)，1467，1376，1251，1035
1HNMR(300MHz，CDCl 3)δppm：0.69(3H，s，18-H 3)，0.94(3H，d，J＝6.26Hz，21-H 3)，1.02(3H，s，19-H 3)，1.16(3H，s，26-H 3)，1.22(3H，s，27-H 3)，2.04(3H，s，CH 3CO 2)，2.31(2H，d，J＝7.68Hz，7-H 2)，3.33(1H，m，24α-H)，4.60(1H，m，3α-H)，5.38(1H，d，J＝4.4Hz，6-H)
Ultimate analysis (C 29H 48O 4): calculated value: C, 75.61%; H, 10.50%
Measured value: C, 75.49%; H, 10.71%
Embodiment 4 Δs 5-3-ethanoyl-3 β, 24S, 25-trihydroxy-courage steroid glycol 6
Figure A9912400700081
In the 100ml egg type bottle, add magneton, 3.257g (9.87mmol) Tripotassium iron hexacyanide, 1.362g salt of wormwood (9.87mmol) 313mgCH 3SO 2NH 2, 128mg (5%mol) (DHQ) 2PHAL, 12mg (1%mol) K 2OsO 2(OH) 4And the mixing solutions of the 33ml trimethyl carbinol and water (1: 1), stirring and dissolving is to even yellow-green soln, add the glycol dimethyl ether contain 1.4g raw material 4 (or N, dinethylformamide, acetonitrile, 1,6-dioxane, N, N-dimethyl acetyl ammonia) solution, stirred 20 hours, and had a large amount of precipitations to separate out, be chilled to 0 ℃, adding the 4.93g S-WAT stirred 1 hour, 3 * 25ml ethyl acetate extraction is used 3 * 75ml 2N KOH respectively, 10% hydrochloric acid, saturated sodium bicarbonate and saturated common salt are washed to neutrality, anhydrous sodium sulfate drying, remove dissolve crude product 1.553g, behind the recrystallization compound 6:1.258 gram, productive rate 83.2%, 98.2%de.
Compound 6:
m.p.：134.9～135.8℃
[α] D 23-27.16°(C，0.928，CHCl 3)
MS(EI)(m/z)：400(M-HOAc)，382(M-HOAc-H 2O)
IR(film)cm -1：3445(OH)，1735(CH 3CO 2)，1469，1376，1248，1035
1HNMR(300MHz，CDCl 3)δppm：0.68(3H，s，18-H 3)，0.94(3H，d，J＝6.54Hz，21-H 3)，1.02(3H，s，19-H 3)，1.18(3H，s，25-H 3)，1.22(3H，s，26-H 3)，2.04(3H，s，CH 3CO 2)，2.32(2H，d，J＝8.23Hz，7-H 2)，3.28(1H，m，24β-H)，4.61(1H，m，3α-H)，5.38(1H，d，J＝4.73，6-H)
Ultimate analysis (C 29H 48O 41/4 H 2O): calculated value: C, 74.88%; H, 10.51%
Measured value: C, 75.08%; H, 10.70%
Embodiment 5 Δs 5-3-(dimethyl-tertiary butyl-silica-based)-3 β, 24R, 25-trihydroxy-courage steroid glycol 8
Figure A9912400700082
In the 25ml egg type bottle, add magneton, 495g K 3Fe (CN) 6, 207mg K 2CO 3, 48mg MeSO 2NH 2, 24mg (5%mol) (DHQD) 2PHAL and 4mg K 2OsO 2(OH) 4And 10ml t-BuOH-H 2O (1: 1) after stirring, adds 1 of 249mg raw material 7, the 6-dioxane (or N, dinethylformamide, glycol dimethyl ether, N, N-dimethyl acetyl ammonia) solution, reaction 20h is chilled to 0 ℃, adds Na 2SO 3Stir 2h.Add the 25ml ethyl acetate, 3 * 25ml2NKOH, 3 * 25ml0%HCl, the saturated NaHCO of 3 * 25ml 3, the saturated NaCl washing of 3 * 25ml, anhydrous Na 2SO 4Dry removing desolvated, and gets compound 8 209mg, yield 78% behind the recrystallization.
Compound 8:
mp：186.0～187.2℃
[α] D 22-9.14°(C，0.504，CHCl 3)
MS-EI(m/z)：532(M +)，517(M-Me)，475(M-tBu)，458(M+1-H 2O-tBu)，440(M+1-tBu-2H 2O)
IR(KBr)cm -1：3420，2933，2860，1382，1254(Si-CH 3)，1096(Si-O)
1HNMR(300MHz，CDCl 3)δppm：0.05(6H，s，Si(CH 3) 2)，0.68(3H，s，18-H 3)，0.88(9H，s，SiC(CH 3) 3)，0.93(3H，d，J＝6.32Hz，21-H 3)，0.99(3H，s，19-H 3)，1.12(3H，s，26-H 3)，1.16(3H，s，27-H 3)，3.33(1H，t，J＝6.36Hz?24α-H)，3.47(1H，m，3α-H)，5.31(1H，d，J＝5.1Hz，6-H)，
Ultimate analysis: calculated value: C, 74.38%; H, 11.35%
Measured value: C, 74.03%; H, 11.51%
Embodiment 6 Δs 5--3-(dimethyl-tertiary butyl-silica-based)-3 β, 24S, 25-trihydroxy-courage steroid glycol 9
In the 50ml egg type bottle, add magneton, 1.812g (5.49mmol) K 3Fe (CN) 6, 758mg (5.49mmol) K 2CO 3, 174mg (1.83mmol) MeSO 2NH 2, 71mg (5%mol) (DHQ) 2PHAL and 20mg (1%mol) K 2OsO 2(OH) 4, and 12mlt-BuOH--H 2O (1: 1) after stirring, adds the N of 913mg (1.83mmol) raw material 7, N-dimethyl acetyl ammonia (or N, dinethylformamide, glycol dimethyl ether, t-butyl methyl ether, 1, the 6-dioxane) solution, raw material disappears substantially after 20 hours, is chilled to 0 ℃, adds 0.915gNa 2SO 3Stir 2H.Add the 50ml ethyl acetate, 3 * 100ml2NKOH, 3 * 100ml0%HCl, the saturated NaHCO of 3 * 100ml 3, the saturated NaCl washing of 3 * 100ml, anhydrous Na 2SO 4Dry remove desolvate crude product 0.919mg, recrystallization gets compound 9 658mg, yield 67%.
Compound 9:
MS(EI)(m/z)：532(M +)，
IR(KBr)cm -1：3422，2935，2858，1382，1255(Si-CH 3)，1097(Si-O)，836
1HNMR(300MHz，CDCl 3)δppm：0.06(6H，s，Si(CH 3) 2)，0.68(3H，s，18-H 3)，0.88(9H，s，SiC(CH 3) 3)，0.91(3H，d，J＝5.06Hz，21-H 3)，1.00(3H，s，19-H 3)，1.17(3H，s，26-H 3)，1.22(3H，s，27-H 3)，3.28(1H，d，J＝8.87Hz，24β-H)，3.48(1H，m，3α-H)，5.30(1H，d，J＝3.36Hz，6-H)，
Ultimate analysis: calculated value: C, 74.38%; H, 11.35%
Measured value: C, 74.21%; H, 11.36%
Embodiment 75 β-3 β, 7 α, 24S, 25-tetrahydroxy courage steroid tetrol 11
Figure A9912400700101
In the 25ml egg type bottle, add magneton, 496mg (1.5mmol) Tripotassium iron hexacyanide, 208mg salt of wormwood (1.5mmol), 48mgCH 3SO 2NH 2, 24mg (5%mol) (DHQ) 2PHAL, 8mg (1%mol) K 2OsO 2(OH) 4And the mixing solutions of 3～5ml trimethyl carbinol and water (1: 1), stirring and dissolving is to even yellow-green soln, add the acetonitrile contain 201mg raw material 10 (or N, dinethylformamide, glycol dimethyl ether, 1,6-dioxane, N, N-dimethyl acetyl ammonia) solution, stirred 20 hours, and had a large amount of precipitations to separate out, be chilled to 0 ℃, adding the 0.75g S-WAT stirred 0.5 hour, 3 * 15ml ethyl acetate extraction is used 3 * 50ml 2N KOH respectively, 10% hydrochloric acid, saturated sodium bicarbonate and saturated common salt are washed to neutrality, anhydrous sodium sulfate drying, remove dissolve crude product 200mg, behind the recrystallization compound 11:185mg, productive rate 85%, 99.3%de.
Compound 11:
MS(EI)(m/z)：400(M-2H 2O)，385(M-2H 2O-Me)
IR(film)cm -1：3445(OH)，1469，1376，1248，1035
1HNMR(300MHz，CDCl 3)δppm：0.66(3H，s，18-H 3)，0.82(3H，s，19-H 3)，0.91(3H，d，J＝6.67Hz，21-H 3)，1.19(3H，s，26-H 3)，1.23(3H，s，27-H 3)，3.29(1H，m，24β-H)，3.53(1H，m，3α-H)，3.85(1H，m，7β-H)，
Embodiment 85 β-3 β, 7 α, 24R, 25-tetrahydroxy courage steroid tetrol 12
Figure A9912400700102
In the 25ml egg type bottle, add magneton, 496mg (1.5mmol) Tripotassium iron hexacyanide, 208g salt of wormwood (1.5m mol), 48mg CH 3SO 2NH 2, 24mg (5%mol) (DHQD) 2PHAL, 8mg (1%mol) K 2OsO 2(OH) 4And the mixing solutions of 3～5ml trimethyl carbinol and water (1: 1), stirring and dissolving is to even yellow-green soln, add the glycol dimethyl ether contain 201mg raw material 10 (or N, dinethylformamide, acetonitrile, acetone, 1, the 6-dioxane, N, N-dimethyl acetyl ammonia) solution, stirred 20 hours, there are a large amount of precipitations to separate out, be chilled to 0 ℃, add the 0.75g S-WAT and stirred 3 * 15ml ethyl acetate extraction 0.5 hour, use 3 * 50ml 2N KOH respectively, 10% hydrochloric acid, saturated sodium bicarbonate and saturated common salt are washed to neutrality, anhydrous sodium sulfate drying, remove dissolve crude product 200mg, get compound 12:187mg, productive rate 86%, 100%de behind the recrystallization.
Compound 12:
MS(EI)(m/z)：400(M-2H 2O)，385(M-2H 2O-Me)
IR(film)cm -1：3448(OH)，1463，1385，1245，1008
1HNMR(300MHz，CDCl 3)δppm：0.64(3H，s，18-H 3)，0.80(3H，s，19-H 3)，0.92(3H，d，J＝6.67Hz，21-H 3)，1.17(3H，s，26-H 3)，1.20(3H，s，27-H 3)，3.32(1H，m，24α-H)，3.52(1H，m，3α-H)，3.82(1H，m，7β-H)，
Embodiment 93-dioxolane-7 alpha-methoxymethyl alkane-7 α, 24S, 25-trihydroxy-courage steroid glycol 14
In the 25ml egg type bottle, add magneton, 496mg (1.5mmol) Tripotassium iron hexacyanide, 208mg salt of wormwood (1.5m mol), 48mg CH 3SO 2NH 2, 24mg (5%mol) (DHQ) 2PHAL, 8mg (1%mol) K 2OsO 2(OH) 4And the mixing solutions of 3～5ml trimethyl carbinol and water (1: 1), stirring and dissolving is to even yellow-green soln, add the tetrahydrofuran (THF) contain 244g raw material 13 (or N, dinethylformamide, second cyanogen, 1,6-dioxane, N, N-dimethyl acetyl ammonia) solution, stirred 20 hours, and had a large amount of precipitations to separate out, be chilled to 0 ℃, adding the 0.75g S-WAT stirred 0.5 hour, 3 * 15ml ethyl acetate extraction is used 3 * 50ml 2N KOH respectively, 10% hydrochloric acid, saturated sodium bicarbonate and saturated common salt are washed to neutrality, anhydrous sodium sulfate drying, remove dissolve crude product 245mg, behind the recrystallization compound 14:219mg, productive rate 84%, 99%de.
Compound 14:
MS(EI)(m/z)：460(M-HOCH 2OCH 3)，442(M-HOCH 2OCH 3-H 2O)，427(M-HOCH 2OCH 3-H 2O-Me)
IR(film)cm -1：3445(OH)，1470，1377，1249，1038
1HNMR(300MHz，CDCl 3)δppm：0.64(3H，s，18-H 3)，0.81(3H，s，19-H 3)，0.92(3H，d，J＝6.68Hz，21-H 3)，1.17(3H，s，25-H 3)，1.21(3H，s，26-H 3)，3.28(1H，m，24β-H)，3.36(3H，s，OCH 3)3.64(1H，m，7β-H)，3.91(4H，m，sharp，OCH 2CH 2O)，4.64(2H，m，OCH 2O)
Embodiment 103-dioxolane-7 alpha-methoxymethyl alkane-7 α, 24R, 25-trihydroxy-courage steroid glycol 15
Figure A9912400700121
In the 25ml egg type bottle, add magneton, 496mg (1.5mmol) Tripotassium iron hexacyanide, 208mg salt of wormwood (1.5mmol), 48mg CH 3SO 2NH 2, 24mg (5%mol) (DHQD) 2PHAL, 8mg (1%mol) K 2OsO 2(OH) 4Mixing solutions with 3～5ml trimethyl carbinol and water (1: 1), stirring and dissolving is to even yellow-green soln, adds the glycol dimethyl ether that contains 244g raw material 13 (or N, dinethylformamide, acetonitrile, 1,6-dioxane, N, N-dimethyl acetyl ammonia) solution, stirred 20 hours, and had a large amount of precipitations to separate out, be chilled to 0 ℃, adding the 0.75g S-WAT stirred 0.5 hour, 3 * 15ml ethyl acetate extraction is used 3 * 50ml 2N KOH respectively, 10% hydrochloric acid, saturated sodium bicarbonate and saturated common salt are washed to neutrality, anhydrous sodium sulfate drying; Remove dissolve crude product 250mg, behind the recrystallization compound 15:227mg, productive rate 87%, 99.6%de.
Compound 15:
MS(EI)(m/z)：460(M-HOCH 2OCH 3)，442(M-HOCH 2OCH 3-H 2O)
IR(film)cm -1：3448(OH)，1468，1375，1245，1031
1HNMR(300MHz，CDCl 3)δppm：0.65(3H，s，18-H 3)，0.81(3H，s，19-H 3)，0.92(3H，d，J＝6.65Hz，21-H 3)，1.18(3H，s，25-H 3)，1.22(3H，s，26-H 3)，3.29(1H，m，24α-H)，3.37(3H，s，OCH 3)3.62(1H，m，7β-H)，3.92(4H，m，sharp，OCH 2CH 2O)，4.65(2H，m，OCH 2O)

Claims (15)

1. 24R, 25-or 24S, the synthetic method of 25-dihydroxyl steroidal compounds, there is down Δ in the mixed solvent catalyst neutralisation that is included in tertiary butanol and water 24-steroidal compounds and K 3Fe (CN) 6, K 2CO 3, CH 3SO 2NH 2React to room temperature at 0 ℃, selected catalyzer is K 2OsO 2(OH) 4(DHQD) 2PHAL or (DHQ) 2PHAL is characterized in that adding second kind of solvent, reacts 10～20 hours, described second kind of solvent is tetrahydrofuran (THF) (THF), N, dinethylformamide (DMF), glycol dimethyl ether (DME), acetonitrile, t-butyl methyl ether (MBE), ether, isopropyl ether, acetone, butanone, 1, the 6-dioxane, N, N-dimethyl acetyl ammonia, described Δ 24-steroidal compounds has following molecular formula:
Figure A9912400700021
R wherein 1Or R 2=methoxy methyl ether (being called for short MOMO), THP trtrahydropyranyl (being called for short THP), acetoxyl group (being called for short AcO), OCH 2CH 2O, OH, H, benzoyl (being called for short PhCOO), methanesulfonates (is called for short MeSO 2O), p-toluenesulfonic esters (being called for short TsO), O, tertiary butyl dimethyl-silicon ether (being called for short TBSO), benzyl (being called for short Bn); R 3=α-or β-H, or R 3R 4=two keys, R 4Or R 5=MOMO, THP, AcO, OCH 2CH 2O, OH, H, PhCOO, MeSO 2O or TsO, O; Or R 4R 5=O, R 6Or R 7=MOMO, THP, AcO, OCH 2CH 2O, OH, H, PhCOO, MeSO 2O, TsO, O, R 6R 7=O.
2. a synthetic method as claimed in claim 1 is characterized in that described Δ 24-steroidal compounds, K 3Fe (CN) 6, K 2CO 3, CH 3SO 2NH 2, K 2OsO 2(OH) 4, 1, two (9-O the dihydro-quinidine)-2 or 1 of 4-, the mol ratio of two (9-O dihydro Kui the Buddhist nun)-2 of 4-is 1: 1～5: 1: 1～5: 0.5～3: 0.005～0.01: 0.005～0.01.
3. a synthetic method as claimed in claim 1 is characterized in that in the mixed solvent of described tertiary butanol and water, and the volume ratio of the trimethyl carbinol and water is 1: 0.5～2.
4. one kind as claim 1 and 3 described synthetic methods, and the consumption that it is characterized in that described tertiary butanol and water mixed solvent is every mole of Δ 24Steroidal compounds adds the mixing solutions of 1～10 liter tertiary butanol and water.
5. synthetic method as claimed in claim 1 is characterized in that reaction product has following molecular formula:
Figure A9912400700022
R wherein 1, R 2, R 3, R 4, R 5, R 6, R 7Described with claim 1.
6. a synthetic method as claimed in claim 1 is characterized in that reaction product is 5 β-3 α, 6 alpha, alpha-dimethyl oxygen ylmethyl-3 α, 6 α, 24R, 25-tetrahydroxy courage steroid glycol.
7. a synthetic method as claimed in claim 1 is characterized in that reaction product is 5 β-3 α, 6 alpha, alpha-dimethyl oxygen ylmethyl-3 α, 6 α, 24S, 25-tetrahydroxy courage steroid glycol.
8. a synthetic method as claimed in claim 1 is characterized in that reaction product is a Δ 5-3 β-ethanoyl-3 β, 24R,
9. a synthetic method as claimed in claim 1 is characterized in that reaction product is a Δ 5-3 β-ethanoyl-3 β, 24S, 25-trihydroxy--courage steroid glycol.
10. a synthetic method as claimed in claim 1 is characterized in that reaction product is a Δ 5Silica-based-3 β of-3 β-(tertiary butyl-dimethyl), 24R, 25-trihydroxy--courage steroid glycol.
11. a synthetic method as claimed in claim 1 is characterized in that reaction product is a Δ 5Silica-based-3 β of-3 β-(tertiary butyl-dimethyl), 24S, 25-trihydroxy--courage steroid glycol.
12. a synthetic method as claimed in claim 1 is characterized in that reaction product is 5 β-3 β, 7 α, 24S, 25-tetrahydroxy courage steroid tetrol.
13. a synthetic method as claimed in claim 1 is characterized in that reaction product is 5 β-3 β, 7 α, 24R, 25-tetrahydroxy courage steroid tetrol.
14. a synthetic method as claimed in claim 1 is characterized in that reaction product is 3-dioxolane-7 alpha-methoxymethyl alkane-7 α, 24S, 25-trihydroxy-courage steroid glycol
15. a synthetic method as claimed in claim 1 is characterized in that reaction product is 3-dioxolane-7 alpha-methoxymethyl alkane-7 α, 24R, 25-trihydroxy-courage steroid glycol
CN99124007A 1999-11-12 1999-11-12 High-stereoselectivity synthesization of 24R,25- and 24S, 25-dihydroxysteroid Expired - Fee Related CN1098273C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN99124007A CN1098273C (en) 1999-11-12 1999-11-12 High-stereoselectivity synthesization of 24R,25- and 24S, 25-dihydroxysteroid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN99124007A CN1098273C (en) 1999-11-12 1999-11-12 High-stereoselectivity synthesization of 24R,25- and 24S, 25-dihydroxysteroid

Publications (2)

Publication Number Publication Date
CN1254716A true CN1254716A (en) 2000-05-31
CN1098273C CN1098273C (en) 2003-01-08

Family

ID=5283105

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99124007A Expired - Fee Related CN1098273C (en) 1999-11-12 1999-11-12 High-stereoselectivity synthesization of 24R,25- and 24S, 25-dihydroxysteroid

Country Status (1)

Country Link
CN (1) CN1098273C (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018064649A1 (en) * 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
US11104701B2 (en) 2013-03-13 2021-08-31 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
US11111266B2 (en) 2016-10-18 2021-09-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11117924B2 (en) 2015-07-06 2021-09-14 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11149054B2 (en) 2016-10-18 2021-10-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11279730B2 (en) 2016-07-07 2022-03-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11407782B2 (en) 2016-05-06 2022-08-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11884697B2 (en) 2016-04-01 2024-01-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09208597A (en) * 1995-11-27 1997-08-12 Kureha Chem Ind Co Ltd Production of steroid compound

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11104701B2 (en) 2013-03-13 2021-08-31 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
US11905309B2 (en) 2013-03-13 2024-02-20 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
US11732000B2 (en) 2015-07-06 2023-08-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11117924B2 (en) 2015-07-06 2021-09-14 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11884697B2 (en) 2016-04-01 2024-01-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11878995B2 (en) 2016-05-06 2024-01-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11407782B2 (en) 2016-05-06 2022-08-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11279730B2 (en) 2016-07-07 2022-03-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11149056B2 (en) 2016-09-30 2021-10-19 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
AU2017337121B2 (en) * 2016-09-30 2022-01-27 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as NMDA modulators
JP7149266B2 (en) 2016-09-30 2022-10-06 セージ セラピューティクス， インコーポレイテッド Methods as C7-Substituted Oxysterols and NMDA Modulators
WO2018064649A1 (en) * 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
JP2019529495A (en) * 2016-09-30 2019-10-17 セージ セラピューティクス， インコーポレイテッド Methods as C7 substituted oxysterols and NMDA modulators
US11926646B2 (en) 2016-09-30 2024-03-12 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
US11613556B2 (en) 2016-10-18 2023-03-28 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11111266B2 (en) 2016-10-18 2021-09-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11149054B2 (en) 2016-10-18 2021-10-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof

Also Published As

Publication number Publication date
CN1098273C (en) 2003-01-08

Similar Documents

Publication Publication Date Title
CN1035555C (en) Processes for diastereoselective synthesis of nucleosides
CN1206207C (en) Preparation method of cyanophthaofluoroaniline
CN1098273C (en) High-stereoselectivity synthesization of 24R,25- and 24S, 25-dihydroxysteroid
CN1235162A (en) New derivatives for erythromycin
CN1131662A (en) Perfluoro unsaturated nitrile compound and process for producing the same
CN100347175C (en) Preparation method of beta-methyl carbon penicillenic intermediate
CA2403429A1 (en) Conversion of 9-dihydro-13-acetylbaccatin iii to baccatin iii and 10-deacetylbaccatin iii
CN1762926A (en) Process for preparing cyclic ketones
CN1709880A (en) AE-active ester chemical synthesizing method
CN1220693C (en) Process for preparation of 3-sulfonyloxy-3-cephem compounds
CN1254470C (en) Process for preparation of baccatin III derivatives
CN1337940A (en) A process for preparing (R)-4-cyano-3-hydroxybutyric acid ester
JP6476591B2 (en) Process for producing (2R) -2-fluoro-2-C-methyl-D-ribono-γ-lactones
CN101041654A (en) Preparation method of cyclohexyl diketone single ketals
CN1197836C (en) Method for asymmetrically synthesizing secondary propiolic alcohol compound
CN1152038C (en) Simple synthesis of D-and L-deoxyribose
CN103130862A (en) Novel synthetic method of ulipristal acetate key intermediate 3, 20-bis (ethylenedioxy)-19-norpregna-5, 9-dien-17-ol
CN1087729C (en) C1-6 fragment compound as intermediate of esperamicin and its usage
CN1016869B (en) Process for preparing 6, 7-diacyl-7-deacetyl forskolin derivatives
CN1634932A (en) Process for preparing cefotaxime sodium
CN1235855C (en) Process for preparation of bicyclic diketone salts
CN1887900A (en) Synthesis of 26-bromo-16, 22-dioxy-cholesterol compounds
CN1644583A (en) Cephe alkene onium salt compound and its preparation and use in preparation of cefepime
CN1086389C (en) Isoesperamicin and its synthesizing process and usage
CN1495176A (en) 4-methyl-5-formylthiazole preparation method

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee